- Category: Medical Cannabis News
- Published: Monday, 28 October 2013 01:19
Washington, DC: The US Food and Drug Administration has approved two clinical trials to assess the efficacy of cannabidiol (CBD), a nonpsychoactive plant cannabinoid, in the treatment of intractable pediatric epilepsy. The two approved trials will take place at New York Medical School and at the University of California at San Francisco, according to an online report in the journal O'Shaughnessy's. The cannabidiol formulations in the trials will be provided by British biotechnology firm GW Pharmaceuticals, which produces organic cannabinoid extract medicines, including Sativex.